scholarly journals Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0165609 ◽  
Author(s):  
Noriaki Arakawa ◽  
Hiroshi Kobayashi ◽  
Naohiro Yonemoto ◽  
Yusuke Masuishi ◽  
Yoko Ino ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tissue Factor ◽  
Clinical Significance ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serum Biomarker ◽  
Ovarian Clear Cell Carcinoma ◽  
Tissue Factor Pathway

scholarly journals Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary

2021 ◽  
Author(s):  
Etsuko Miyagi ◽  
Noriaki Arakawa ◽  
Kentaro Sakamaki ◽  
Naho Ruiz Yokota ◽  
Takeharu Yamanaka ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Benign Lesions ◽  
Cancer Antigen 125 ◽  
Serum Samples ◽  
Ovarian Endometriosis ◽  
Tissue Factor Pathway

Abstract Background Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we examined the performance of TFPI2 for preoperative diagnosis of CCC. Methods Serum samples were obtained preoperatively from patients with ovarian masses, who needed surgical treatment at five hospitals in Japan. The diagnostic powers of TFPI2 and cancer antigen 125 (CA125) serum levels to discriminate CCC from BOTs, other EOCs, and benign lesions were compared. Results A total of 351 patients including 69 CCCs were analyzed. Serum TFPI2 levels were significantly higher in CCC patients (mean ± SD, 508.2 ± 812.0 pg/mL) than in patients with benign lesions (154.7 ± 46.5), BOTs (181 ± 95.5) and other EOCs (265.4 ± 289.1). TFPI2 had a high diagnostic specificity for CCC (79.5%). In patients with benign ovarian endometriosis, no patient was positive for TFPI2, but 71.4% (15/21) were CA125 positive. TFPI2 showed good performance in discriminating stage II–IV CCC from BOTs and other EOCs (AUC 0.815 for TFPI2 versus 0.505 for CA125) or endometriosis (AUC 0.957 for TFPI2 versus 0.748 for CA125). The diagnostic sensitivity of TFPI2 to discriminate CCC from BOTs and other EOCs was improved from 43.5 to 71.0% when combined with CA125. Conclusions High specificity of TFPI2 for preoperative detection of CCC was verified with the defined cutoff level of TFPI2 in clinical practice. TFPI2 and CA125 may contribute substantially to precise prediction of intractable CCC.

Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration

2020 ◽  
Vol 40 (12) ◽  
pp. 6791-6798
Author(s):  
MARIKO MIYAZAWA ◽  
MASANORI YASUDA ◽  
MASAKI MIYAZAWA ◽  
NAOKI OGANE ◽  
TOMOMI KATOH ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor ◽  
Carcinoma Cells ◽  
Ovarian Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor 1Α

scholarly journals Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (39) ◽  
pp. 62925-62938 ◽  
Author(s):  
I-Ling Hsu ◽  
Cheng-Yang Chou ◽  
Yi-Ying Wu ◽  
Jia-En Wu ◽  
Chen-Hsien Liang ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Carcinoma ◽  
Cardiac Glycosides ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma

scholarly journals Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Huijuan Ge ◽  
Yaoxin Xiao ◽  
Guangqi Qin ◽  
Yanzi Gu ◽  
Xu Cai ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Tissue Microarrays ◽  
Ovarian Clear Cell Carcinoma ◽  
Repair Deficiency ◽  
Ovarian Epithelial Carcinoma ◽  
Histological Characteristics ◽  
Infiltrating Lymphocytes

Abstract Background Ovarian clear cell carcinoma (OCCC) is the second subtype of ovarian epithelial carcinoma reported to be closely related to Lynch syndrome (LS). ARID1A mutation is an important pathogenetic mechanism in OCCC that leads to loss of ARID1A expression in approximately half of OCCCs. However, the correlation of MMR status and ARID1A deficiency is unclear. The current study aimed to identify the clinical and histopathological characteristics of OCCC associated with dMMR and to further explore the association between dMMR and ARID1A deficiency. Methods A cohort of 176 primary OCCC patients was enrolled and review included histological characteristics (nuclear atypia, necrosis, mitosis, stromal hyalinization, and background precursors) and host inflammatory response (tumor-infiltrating lymphocytes, peritumoral lymphocytes, intratumoral stromal inflammation and plasma cell infiltration). Immunohistochemical staining of MLH1, PMS2, MSH2, MSH6 and ARID1A was performed using tissue microarrays. Results dMMR was detected in 10/176 tumors (6 %), followed by MSH2/MSH6 (6/176), MLH1/PMS2 (3/176), and MSH6 (1/176). The average age of patients with dMMR was younger than that of patients with intact MMR (46 y vs. 53 y). Tumors with diffuse intratumoral stromal inflammation remained significantly associated after multivariate analysis. ARID1A expression was absent in 8 patients with dMMR (8/10), which is a significantly higher frequency than that observed in patients with intact MMR (80 % vs. 43.2 %). Conclusions Our study indicates that diffuse intratumoral stromal inflammation of OCCCs is associated with dMMR, with loss of MSH2/MSH6 expression being most frequent. dMMR is strongly associated with the loss of ARID1A expression in OCCC.

Sign in / Sign up

Export Citation Format

Share Document